May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict paravalvular leak (PVL) in patients undergoing transcatheter aortic valve replacement (TAVR). A common risk of TAVR is an ill-fitting valve which can lead to PVL. To address this risk, the study used 3-D printing technology to help confirm and detect the location of the leak.

The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and Treatment Resource Center. This center will be an ongoing, patient-centered quality improvement initiative focused on helping increase peripheral artery disease (PAD) awareness in the cardiovascular and internal medicine community by delving into the underlying risks of this disease state.

May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented as late-breaking clinical science at 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions.

May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hospitalized with endocarditis has increased dramatically over the last decade in a pattern that mirrors the increase in mixed drug use. The nearly decade-long retrospective study analyzed patients in the epicenter of the opioid epidemic — West Virginia. Findings showed a trend between the significant increase in patients hospitalized with endocarditis from mixed drug abuse and the substantial cost it has on state and federal programs.

Richard Schatz, M.D., (center) is research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program. #SCAI, #SCAI2018

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

 

Late-breaking Studies:

May 14, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine was honored with a Silver national Azbee Award for editorial excellence at the 2018 National American Society of Business Publication Editors (ASBPE)  Azbee Awards of Excellence banquet in May in Washington, D.C.  DAIC and Editor Dave Fornell were recognized in the Online Blog Analysis/Commentary category for Fornell’s blog series “Insights Into Cardiovascular Technology Advances.”

Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from the U.S. Food and Drug Administration (FDA) to enroll a second group of subjects and expand to 15 heart centers across the United States.

TREAT Symposium (TransRadial Endovascular Advanced Therapies)

A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR). This first-ever tool calculates a score to help clinicians and medical professionals predict risk of 30-day readmission for TAVR patients and can be easily incorporated in patient electronic medical records (EMR). The study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego.

Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego. The FLARE study is a prospective, single-arm multicenter trial designed to evaluate the safety and efficacy of the Flowtriever system (Inari Medical, Irvine, Calif.) in patients with acute pulmonary embolism (PE). It is the first trial to treat pulmonary embolism without using thrombolytics, the use of drugs to break up or dissolve blood clots that can lead to bleeding complications.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now